KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Assets (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Current Assets for 15 consecutive years, with $644.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 6.11% to $644.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $644.2 million through Dec 2025, down 6.11% year-over-year, with the annual reading at $644.2 million for FY2025, 6.11% down from the prior year.
  • Current Assets for Q4 2025 was $644.2 million at Supernus Pharmaceuticals, up from $593.9 million in the prior quarter.
  • The five-year high for Current Assets was $883.3 million in Q1 2023, with the low at $423.5 million in Q2 2023.
  • Average Current Assets over 5 years is $623.1 million, with a median of $632.2 million recorded in 2021.
  • The sharpest move saw Current Assets soared 55.38% in 2023, then plummeted 38.38% in 2024.
  • Over 5 years, Current Assets stood at $601.6 million in 2021, then grew by 22.04% to $734.2 million in 2022, then tumbled by 32.83% to $493.1 million in 2023, then surged by 39.13% to $686.1 million in 2024, then fell by 6.11% to $644.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $644.2 million, $593.9 million, and $738.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.